Natera, INC Form 4 insider transactions

Director James Healy reports the acquisition of 114 Restricted Stock Units (RSUs) from Natera, Inc. in lieu of quarterly retainer fees.

Director Roelof Botha acquired 151 shares of Natera, Inc. common stock through the issuance of fully vested RSUs in lieu of quarterly retainer fees.

Director Roy D. Baynes acquired 92 shares of Natera, Inc. common stock through the issuance of fully vested Restricted Stock Units (RSUs) in lieu of quarterly retainer fees.

Natera's Chief Financial Officer, Michael Brophy, sold a total of 6,221 shares of common stock across multiple transactions to cover tax obligations and under a pre-arranged trading plan.

Natera co-founder Jonathan Sheena sold a total of 1,217 shares of common stock across three transactions to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

Natera's Executive Chairman, Matthew Rabinowitz, sold a portion of his shares to cover tax obligations related to vesting Restricted Stock Units (RSUs).

A Natera executive, Daniel Rabinowitz, sold shares to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

A Natera executive, Solomon Moshkevich, sold shares to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

A Natera executive, John Fesko, sold shares to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

Natera's CEO, Steven Leonard Chapman, sold shares to cover tax obligations related to the vesting of Restricted Stock Units (RSUs).

Natera co-founder Jonathan Sheena reported a charitable donation of 588 common stock shares on January 27, 2025.

Natera's Chief Financial Officer, Michael Burkes Brophy, sold 1,442 shares of common stock at $161.87 per share on January 27, 2025, under a pre-arranged 10b5-1 trading plan.

Natera's Chief Financial Officer, Michael Brophy, sold a portion of his shares to cover tax obligations related to vesting restricted stock units.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold shares to cover tax obligations related to vesting of Restricted Stock Units (RSUs).

A Natera executive, John Fesko, sold shares to cover tax obligations related to vesting of restricted stock units.

Natera's co-founder recently exercised stock options and sold a portion of shares to cover tax obligations, according to a recent SEC filing.'

Natera's SEC. AND CHIEF LEGAL OFFICER, Daniel Rabinowitz, reports the acquisition and sale of company stock and restricted stock units.

Natera CEO Steven Chapman sold 78,553 shares of common stock to cover tax obligations after the vesting of restricted stock units.

Natera's Chief Financial Officer, Michael Brophy, sold shares to cover tax obligations following the vesting of restricted stock units.

Natera co-founder Jonathan Sheena reports the vesting of restricted stock units and subsequent acquisition of common stock on January 16, 2025.

Daniel Rabinowitz, Natera's SEC. AND CHIEF LEGAL OFFICER, reported the vesting of restricted stock units and subsequent acquisition of common stock on January 16, 2025.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, acquired a total of 48,548 shares of common stock through the vesting of performance-based Restricted Stock Units (RSUs).

Natera's President and Chief Business Officer, John Fesko, acquired a total of 54,316 shares of common stock on January 16, 2025, through the vesting of performance-based Restricted Stock Units (RSUs).

Natera CEO Steven Chapman exercised stock options and received performance-based restricted stock units, resulting in a change in his beneficial ownership of company stock.

Natera's Chief Financial Officer, Michael Brophy, acquired 39,730 shares of common stock and 24,348 shares through the vesting of restricted stock units on January 16, 2025.

Daniel Rabinowitz, SEC. AND CHIEF LEGAL OFFICER of Natera, Inc., sold 6,223 shares of common stock at an average price of $175.3015 per share.

Natera co-founder Jonathan Sheena sold a total of 6,260 shares of common stock on January 2, 2025, through pre-arranged 10b5-1 trading plans.

Natera's President and Chief Business Officer, John Fesko, acquired 1,675 shares of common stock through vested Restricted Stock Units (RSUs) and subsequently sold shares to cover tax obligations.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold a portion of his shares to cover tax obligations after the vesting of restricted stock units.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, reported donating shares of company stock to charity in two separate transactions.